PMcardio Expands Heart Attack Detection to Patient Bedside through Roche cobas® pulse Point of Care Platform

Powerful Medical has partnered with Roche to integrate AI-powered ECG interpretation from PMcardio into the cobas® pulse point-of-care platform. Combined with Roche’s Elecsys® high-sensitivity cardiac Troponin T assay, this solution enables clinicians to rapidly and accurately rule in or rule out heart attacks directly at the patient’s bedside.

• Powerful Medical collaborates with Roche to bring real-time AI-powered ECG interpretation from PMcardio to the cobas® pulse system, streamlining chest pain diagnostics at the point of care
• This solution, combined with Roche’s Elecsys® high-sensitivity cardiac Troponin T testing, will allow healthcare professionals to make confident clinical decisions in ruling in or ruling out heart attacks (acute myocardial infarction)
• Cardiovascular disease causes a third of worldwide deaths, with chest pain being the second highest reason for emergency department (ED) visits

Powerful Medical today announced its collaboration with Roche to offer PMcardio, the leading AI-driven electrocardiogram (ECG) interpretation solution, as part of the cobas® pulse ecosystem—a next-generation point-of-care platform. This collaboration aims to enhance the diagnostic pathway for patients presenting with chest pain, one of the most common reasons for Emergency Department (ED) visits.

Each year, chest pain accounts for millions of emergency department visits. Rapid ECG interpretation is the primary tool for diagnosing ST-elevation myocardial infarction (STEMI)—the most acute form of heart attack—and guiding timely decisions to ensure patients reach the catheterization laboratory within 90 minutes, preventing irreversible damage and reducing mortality. When the ECG does not indicate STEMI, high-sensitivity cardiac troponin testing becomes the gold standard for confirming or safely ruling out myocardial infarction.

Through the combined strengths of PMcardio and the cobas® pulse system, advanced AI-powered ECG interpretation and smart point of care biomarker testing are now available within a single system at the patient’s bedside. This collaboration enables faster, more accurate clinical decisions at the point of care—enhancing diagnostic confidence and streamlining the pathway for identifying acute MI, including STEMI and its equivalents, in real time.

“We aim to deliver the fastest and most accurate pathway for both ruling out and ruling in acute MI. With the combined use of AI ECG and high-sensitivity troponin T, we can close the diagnostic gap—and ultimately improve outcomes for patients presenting with chest pain and reduce healthcare costs,” Dr. Robert Herman, PhD, Chief Medical Officer, Powerful Medical.

PMcardio is teaming up with Roche to help build the most complete, digitally enhanced, and time-sensitive diagnostic pathway for chest pain patients, right at the point of care. This strengthens PMcardio’s position as a scalable, clinically trusted AI platform.

About PMcardio and Powerful Medical

PMcardio is a diagnostic and care coordination platform developed by Powerful Medical, a medical device manufacturer specializing in AI-driven cardiovascular diagnostics. Clinically validated to detect 49 cardiac conditions from an ECG, it identifies acute heart attacks up to three hours earlier and with twice the sensitivity of the current standard of care. This enables timely and accurate triage in emergency settings. By reducing treatment delays and door-to-balloon times, PMcardio facilitates optimized care for chest pain patients. Already class IIb CE-marked under EU MDR in Europe, and pending FDA approval, it enhances acute cardiac care by supporting faster, more confident clinical decisions.

All trademarks used or mentioned in this release are protected by law.